Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
4930468A 15Rik | |
AK015525 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930468A15 product:hypothetical protein, full insert sequence [AK015525] |
KLA | .97 |
1.00 |
1.03 |
.98 |
1.02 |
1.01 |
1.02 |
| ATP | 1.03 |
.97 |
1.05 |
1.02 |
.99 |
.98 |
.98 |
| KLA/ATP | 1.01 |
1.00 |
.97 |
1.01 |
.95 |
.98 |
.96 |
|
Akt1 | |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 | |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 | |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Araf | |
NM_009703 |
v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] |
KLA | .87 |
.80 |
.89 |
.93 |
1.10 |
1.19 |
1.16 |
| ATP | 1.09 |
1.11 |
1.19 |
1.18 |
.78 |
.53 |
1.18 |
| KLA/ATP | 1.00 |
.95 |
.99 |
.93 |
.63 |
.55 |
1.27 |
|
BB229853
| |
BB229853 |
gb|BB229853 RIKEN full-length enriched, 3 days neonate thymus Mus musculus cDNA clone A630023O21 3. [BB229853] |
KLA | 6.32 |
5.94 |
6.13 |
6.41 |
7.39 |
12.33 |
6.08 |
| ATP | .39 |
.24 |
.33 |
.38 |
1.18 |
5.75 |
2.85 |
| KLA/ATP | 2.27 |
2.02 |
3.25 |
4.04 |
7.11 |
10.22 |
13.93 |
|
Bad | |
AK029400 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] |
KLA | 1.15 |
1.22 |
1.26 |
1.31 |
1.40 |
1.67 |
1.59 |
| ATP | .95 |
1.06 |
1.12 |
1.06 |
.78 |
.89 |
1.27 |
| KLA/ATP | 1.25 |
1.39 |
1.33 |
1.29 |
1.11 |
.91 |
1.38 |
|
Braf | |
NM_139294 |
Braf transforming gene (Braf), mRNA [NM_139294] |
KLA | 1.52 |
1.57 |
1.55 |
1.33 |
1.83 |
1.52 |
1.60 |
| ATP | 1.08 |
1.17 |
1.02 |
1.37 |
.95 |
1.15 |
.95 |
| KLA/ATP | 1.64 |
1.69 |
1.39 |
1.51 |
1.04 |
1.31 |
1.26 |
|
Cd81 | |
NM_133655 |
CD 81 antigen (Cd81), mRNA [NM_133655] |
KLA | .80 |
.79 |
.78 |
.74 |
.59 |
.45 |
.25 |
| ATP | .89 |
.74 |
.63 |
.54 |
.45 |
.57 |
.47 |
| KLA/ATP | .75 |
.67 |
.65 |
.51 |
.45 |
.39 |
.41 |
|
Cdkn1a | |
NM_007669 |
cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] |
KLA | 4.72 |
4.90 |
4.96 |
3.73 |
2.11 |
1.14 |
1.02 |
| ATP | 1.14 |
1.52 |
.95 |
1.69 |
1.47 |
2.21 |
.50 |
| KLA/ATP | 5.99 |
7.08 |
3.86 |
6.37 |
3.00 |
2.55 |
2.05 |
|
Chuk | |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Cldn1 | |
NM_016674 |
claudin 1 (Cldn1), mRNA [NM_016674] |
KLA | .97 |
1.02 |
1.02 |
1.05 |
1.05 |
.99 |
1.07 |
| ATP | 1.02 |
.94 |
1.03 |
1.08 |
1.05 |
.98 |
1.02 |
| KLA/ATP | 1.03 |
1.02 |
1.00 |
1.00 |
1.17 |
1.01 |
1.03 |
|
Cldn10 | |
NM_021386 |
claudin 10 (Cldn10), transcript variant 2, mRNA [NM_021386] |
KLA | 1.06 |
1.05 |
1.04 |
1.12 |
1.08 |
1.05 |
1.04 |
| ATP | 1.07 |
.97 |
.98 |
1.06 |
1.00 |
1.01 |
.97 |
| KLA/ATP | 1.01 |
1.06 |
.86 |
.98 |
1.03 |
1.04 |
1.09 |
|
Cldn11 | |
NM_008770 |
claudin 11 (Cldn11), mRNA [NM_008770] |
KLA | 1.05 |
1.10 |
1.04 |
.99 |
.97 |
.99 |
.97 |
| ATP | 1.03 |
1.01 |
1.08 |
3.05 |
1.24 |
1.11 |
1.07 |
| KLA/ATP | 1.02 |
.96 |
1.42 |
2.53 |
1.09 |
1.02 |
1.03 |
|
Cldn13 | |
NM_020504 |
claudin 13 (Cldn13), mRNA [NM_020504] |
KLA | 1.02 |
1.00 |
1.02 |
.97 |
1.01 |
.98 |
.99 |
| ATP | .92 |
.96 |
1.05 |
.96 |
1.02 |
1.04 |
1.04 |
| KLA/ATP | .93 |
.94 |
1.10 |
1.06 |
1.00 |
.93 |
1.03 |
|
Cldn14 | |
NM_019500 |
claudin 14 (Cldn14), mRNA [NM_019500] |
KLA | 1.03 |
1.12 |
1.14 |
1.08 |
1.09 |
1.16 |
1.08 |
| ATP | 1.03 |
.99 |
1.12 |
1.04 |
1.07 |
1.10 |
1.06 |
| KLA/ATP | 1.07 |
1.14 |
1.21 |
1.12 |
1.07 |
1.10 |
1.08 |
|
Cldn15 | |
NM_021719 |
claudin 15 (Cldn15), mRNA [NM_021719] |
KLA | 1.01 |
1.07 |
1.04 |
1.09 |
1.06 |
1.11 |
.98 |
| ATP | 1.17 |
1.26 |
1.27 |
1.08 |
1.24 |
1.11 |
1.05 |
| KLA/ATP | 1.25 |
1.31 |
1.19 |
1.22 |
1.70 |
1.26 |
1.03 |
|
Cldn16 | |
NM_053241 |
claudin 16 (Cldn16), mRNA [NM_053241] |
KLA | 1.08 |
.98 |
1.02 |
1.00 |
1.06 |
1.05 |
1.00 |
| ATP | 1.01 |
1.05 |
1.01 |
1.12 |
1.05 |
.98 |
.99 |
| KLA/ATP | .98 |
.95 |
1.04 |
1.05 |
1.02 |
1.15 |
1.01 |
|
Cldn17 | |
NM_181490 |
claudin 17 (Cldn17), mRNA [NM_181490] |
KLA | .99 |
1.05 |
1.01 |
1.00 |
.97 |
.99 |
1.01 |
| ATP | .95 |
.98 |
1.06 |
1.05 |
.97 |
1.00 |
1.00 |
| KLA/ATP | 1.04 |
1.00 |
.95 |
1.05 |
.96 |
1.02 |
1.11 |
|
Cldn18 | |
NM_019815 |
claudin 18 (Cldn18), mRNA [NM_019815] |
KLA | .99 |
1.06 |
.99 |
.99 |
1.03 |
1.13 |
1.11 |
| ATP | .96 |
1.00 |
1.10 |
.98 |
.95 |
.98 |
1.07 |
| KLA/ATP | 1.07 |
.95 |
1.05 |
1.07 |
1.11 |
1.06 |
1.02 |
|
Cldn19 | |
NM_001038590 |
claudin 19 (Cldn19), transcript variant 1, mRNA [NM_001038590] |
KLA | 1.06 |
.92 |
1.01 |
1.01 |
1.03 |
.96 |
1.00 |
| ATP | 1.00 |
.97 |
1.05 |
.93 |
.95 |
.91 |
1.01 |
| KLA/ATP | .93 |
.99 |
.96 |
.93 |
.91 |
.92 |
.93 |
|
Cldn19 | |
NM_153105 |
claudin 19 (Cldn19), transcript variant 2, mRNA [NM_153105] |
KLA | .97 |
1.01 |
1.02 |
1.05 |
1.06 |
.96 |
1.09 |
| ATP | 1.04 |
.98 |
1.08 |
1.02 |
.98 |
1.00 |
.96 |
| KLA/ATP | 1.02 |
1.03 |
1.03 |
1.02 |
1.00 |
1.02 |
1.03 |
|
Cldn2 | |
NM_016675 |
claudin 2 (Cldn2), mRNA [NM_016675] |
KLA | .98 |
.93 |
1.02 |
1.04 |
1.00 |
1.03 |
1.01 |
| ATP | 1.01 |
1.01 |
1.00 |
1.06 |
1.01 |
.99 |
1.08 |
| KLA/ATP | 1.07 |
1.01 |
.72 |
1.04 |
1.04 |
1.04 |
1.00 |
|
Cldn22 | |
NM_029383 |
claudin 22 (Cldn22), mRNA [NM_029383] |
KLA | .99 |
.99 |
.99 |
.99 |
.99 |
.98 |
.96 |
| ATP | 1.01 |
.95 |
.99 |
.98 |
1.06 |
.92 |
.98 |
| KLA/ATP | 1.02 |
1.07 |
.96 |
1.00 |
1.02 |
1.04 |
.99 |
|
Cldn23 | |
NM_027998 |
claudin 23 (Cldn23), mRNA [NM_027998] |
KLA | 1.33 |
1.38 |
1.29 |
1.23 |
1.13 |
1.13 |
1.20 |
| ATP | .99 |
1.04 |
1.11 |
1.41 |
1.44 |
1.23 |
1.14 |
| KLA/ATP | 1.42 |
1.34 |
1.29 |
1.33 |
1.30 |
1.23 |
1.73 |
|
Cldn3 | |
NM_009902 |
claudin 3 (Cldn3), mRNA [NM_009902] |
KLA | 1.04 |
1.02 |
1.06 |
1.09 |
1.08 |
1.13 |
1.09 |
| ATP | 1.02 |
1.02 |
1.06 |
1.03 |
1.01 |
1.00 |
1.01 |
| KLA/ATP | 1.07 |
1.05 |
1.19 |
1.10 |
1.07 |
1.13 |
1.15 |
|
Cldn4 | |
NM_009903 |
claudin 4 (Cldn4), mRNA [NM_009903] |
KLA | 1.05 |
.99 |
.94 |
1.02 |
1.05 |
1.05 |
.98 |
| ATP | 1.01 |
1.04 |
1.01 |
.95 |
.96 |
1.09 |
1.09 |
| KLA/ATP | .98 |
1.11 |
1.08 |
1.05 |
.86 |
.95 |
1.07 |
|
Cldn5 | |
NM_013805 |
claudin 5 (Cldn5), mRNA [NM_013805] |
KLA | 1.08 |
1.08 |
1.23 |
1.13 |
1.16 |
1.18 |
1.18 |
| ATP | 1.01 |
1.02 |
1.03 |
1.03 |
1.05 |
1.00 |
1.06 |
| KLA/ATP | 1.14 |
1.18 |
1.13 |
1.09 |
1.05 |
1.15 |
1.16 |
|
Cldn6 | |
NM_018777 |
claudin 6 (Cldn6), mRNA [NM_018777] |
KLA | 1.06 |
1.04 |
.98 |
1.01 |
1.03 |
.99 |
.91 |
| ATP | .98 |
1.01 |
.94 |
.99 |
.95 |
1.14 |
1.07 |
| KLA/ATP | 1.02 |
.96 |
1.08 |
1.04 |
1.01 |
.95 |
1.05 |
|
Cldn7 | |
NM_016887 |
claudin 7 (Cldn7), mRNA [NM_016887] |
KLA | 1.21 |
1.23 |
1.33 |
1.38 |
1.44 |
1.26 |
1.01 |
| ATP | 1.01 |
1.01 |
1.07 |
1.01 |
1.04 |
1.04 |
1.03 |
| KLA/ATP | 1.22 |
1.28 |
1.24 |
2.23 |
1.42 |
1.17 |
1.07 |
|
Cldn8 | |
NM_018778 |
claudin 8 (Cldn8), mRNA [NM_018778] |
KLA | .98 |
.86 |
1.00 |
.98 |
1.02 |
1.06 |
.97 |
| ATP | .93 |
.99 |
1.01 |
1.00 |
1.05 |
1.01 |
1.03 |
| KLA/ATP | .98 |
1.08 |
.96 |
1.00 |
1.02 |
.98 |
1.00 |
|
Cldn9 | |
NM_020293 |
claudin 9 (Cldn9), mRNA [NM_020293] |
KLA | 1.29 |
1.24 |
1.37 |
1.34 |
1.32 |
1.37 |
1.55 |
| ATP | .92 |
.90 |
1.30 |
1.47 |
1.43 |
1.32 |
1.12 |
| KLA/ATP | 1.16 |
1.26 |
2.03 |
1.63 |
1.89 |
1.39 |
1.30 |
|
D430028G 21Rik | |
NM_144888 |
RIKEN cDNA D430028G21 gene (D430028G21Rik), mRNA [NM_144888] |
KLA | .56 |
.54 |
.61 |
.60 |
.74 |
1.03 |
1.06 |
| ATP | 1.07 |
.99 |
.69 |
.66 |
.48 |
.96 |
1.38 |
| KLA/ATP | .61 |
.60 |
.38 |
.41 |
.42 |
1.00 |
1.40 |
|
Ddx58 | |
NM_172689 |
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (Ddx58), mRNA [NM_172689] |
KLA | 8.80 |
9.12 |
9.70 |
9.96 |
9.92 |
7.85 |
5.67 |
| ATP | 1.06 |
.89 |
.97 |
.89 |
.80 |
3.03 |
3.67 |
| KLA/ATP | 9.18 |
9.23 |
10.31 |
9.25 |
7.29 |
6.93 |
8.99 |
|
Egf | |
NM_010113 |
epidermal growth factor (Egf), mRNA [NM_010113] |
KLA | .89 |
.90 |
.81 |
.83 |
.83 |
.86 |
.92 |
| ATP | 1.03 |
1.03 |
.95 |
.84 |
.67 |
.79 |
.88 |
| KLA/ATP | .86 |
.86 |
.77 |
.77 |
.69 |
.78 |
.83 |
|
Egfr | |
NM_007912 |
epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] |
KLA | 1.10 |
1.07 |
1.14 |
1.11 |
1.08 |
1.03 |
.90 |
| ATP | .99 |
1.00 |
1.04 |
.98 |
.97 |
1.15 |
1.14 |
| KLA/ATP | 1.07 |
1.10 |
1.16 |
1.08 |
1.01 |
.97 |
.94 |
|
Egfr | |
NM_207655 |
epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] |
KLA | 1.57 |
1.44 |
1.47 |
1.31 |
.96 |
.92 |
.76 |
| ATP | .97 |
.93 |
1.10 |
1.00 |
1.41 |
2.97 |
.86 |
| KLA/ATP | 1.44 |
1.50 |
1.61 |
1.30 |
1.14 |
1.21 |
.82 |
|
Eif2ak1 | |
AK032508 |
adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430574E03 product:EUKARYOTIC TRANSLATION INITIATION FACTOR 2 ALPHA KINASE 1 (EC 2.7.1.-) (HEME-REGULATED EUKARYOTIC INITIATION FACTOR EIF-2-ALPHA KINASE) (HEME-R |
KLA | .65 |
.66 |
.65 |
.67 |
.67 |
.85 |
1.06 |
| ATP | 1.07 |
1.13 |
1.10 |
1.03 |
.70 |
.63 |
.72 |
| KLA/ATP | .68 |
.73 |
.70 |
.67 |
.65 |
.66 |
.47 |
|
Eif2ak1 | |
NM_013557 |
eukaryotic translation initiation factor 2 alpha kinase 1 (Eif2ak1), mRNA [NM_013557] |
KLA | 1.16 |
1.19 |
1.32 |
1.21 |
1.58 |
1.51 |
1.59 |
| ATP | 1.19 |
1.27 |
.93 |
1.28 |
1.02 |
1.53 |
1.60 |
| KLA/ATP | 1.36 |
1.50 |
1.16 |
1.38 |
1.12 |
1.79 |
2.42 |
|
Eif2ak2 | |
NM_011163 |
eukaryotic translation initiation factor 2-alpha kinase 2 (Eif2ak2), mRNA [NM_011163] |
KLA | 6.20 |
6.38 |
6.31 |
6.36 |
4.86 |
4.86 |
2.93 |
| ATP | 1.03 |
.78 |
.68 |
.37 |
.49 |
3.38 |
1.97 |
| KLA/ATP | 6.50 |
5.52 |
5.25 |
2.87 |
3.90 |
4.33 |
3.35 |
|
Eif2ak3 | |
AK041698 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630030N06 product:unclassifiable, full insert sequence. [AK041698] |
KLA | .79 |
.77 |
.83 |
.80 |
.93 |
.87 |
.85 |
| ATP | .82 |
.82 |
.82 |
.92 |
.88 |
.85 |
.91 |
| KLA/ATP | .77 |
.76 |
.78 |
.80 |
.84 |
.86 |
.81 |
|
Eif2ak3 | |
NM_010121 |
eukaryotic translation initiation factor 2 alpha kinase 3 (Eif2ak3), mRNA [NM_010121] |
KLA | .28 |
.28 |
.27 |
.29 |
.38 |
.36 |
.47 |
| ATP | 1.17 |
1.04 |
.62 |
.48 |
.54 |
.48 |
.67 |
| KLA/ATP | .29 |
.30 |
.26 |
.26 |
.34 |
.37 |
.32 |
|
Eif2ak4 | |
AF193344 |
GCN2gamma mRNA, complete cds [AF193344] |
KLA | .78 |
.78 |
.66 |
.72 |
.79 |
.83 |
1.05 |
| ATP | .97 |
1.06 |
.97 |
.97 |
.98 |
.86 |
.94 |
| KLA/ATP | .81 |
.73 |
.62 |
.84 |
.81 |
.88 |
.90 |
|
Eif2ak4 | |
NM_013719 |
eukaryotic translation initiation factor 2 alpha kinase 4 (Eif2ak4), mRNA [NM_013719] |
KLA | .60 |
.55 |
.49 |
.54 |
.59 |
.67 |
.91 |
| ATP | 1.11 |
1.18 |
1.00 |
.94 |
1.33 |
.90 |
.98 |
| KLA/ATP | .59 |
.54 |
.56 |
.58 |
.90 |
.86 |
.86 |
|
Eif2s1 | |
NM_026114 |
eukaryotic translation initiation factor 2, subunit 1 alpha (Eif2s1), mRNA [NM_026114] |
KLA | 1.50 |
1.49 |
1.52 |
1.49 |
1.24 |
1.12 |
1.25 |
| ATP | 1.00 |
.98 |
1.16 |
1.05 |
1.03 |
1.10 |
.99 |
| KLA/ATP | 1.50 |
1.54 |
1.73 |
1.39 |
1.24 |
.87 |
.66 |
|
Eif3e | |
NM_008388 |
eukaryotic translation initiation factor 3, subunit E (Eif3e), mRNA [NM_008388] |
KLA | 1.24 |
1.29 |
1.21 |
1.17 |
.99 |
.75 |
.84 |
| ATP | .96 |
1.02 |
1.23 |
1.34 |
1.05 |
.77 |
.49 |
| KLA/ATP | 1.13 |
1.24 |
1.32 |
1.46 |
1.05 |
.65 |
.39 |
|
Grb2 | |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 | |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Gsk3b | |
NM_019827 |
glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] |
KLA | 1.06 |
1.03 |
1.11 |
1.01 |
1.26 |
1.28 |
1.26 |
| ATP | 1.18 |
1.27 |
1.15 |
2.07 |
2.37 |
2.32 |
1.67 |
| KLA/ATP | 1.15 |
1.21 |
.98 |
1.50 |
1.67 |
2.50 |
2.99 |
|
Hras1 | |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Ifit1 | |
NM_008331 |
interferon-induced protein with tetratricopeptide repeats 1 (Ifit1), mRNA [NM_008331] |
KLA | 135.72 |
113.87 |
103.77 |
80.36 |
56.00 |
83.83 |
37.35 |
| ATP | 1.04 |
.85 |
.94 |
.76 |
2.31 |
49.86 |
32.09 |
| KLA/ATP | 125.55 |
117.42 |
90.59 |
105.68 |
85.74 |
135.36 |
156.56 |
|
Ifna12 | |
NM_177361 |
interferon alpha 12 (Ifna12), mRNA [NM_177361] |
KLA | 1.25 |
1.26 |
1.34 |
1.16 |
1.06 |
1.10 |
1.09 |
| ATP | 1.01 |
.97 |
1.07 |
1.09 |
1.17 |
1.20 |
1.07 |
| KLA/ATP | 1.12 |
1.29 |
1.72 |
1.54 |
1.59 |
1.56 |
1.05 |
|
Ifna13 | |
NM_177347 |
interferon alpha 13 (Ifna13), mRNA [NM_177347] |
KLA | 1.32 |
1.27 |
1.26 |
1.34 |
1.15 |
1.24 |
1.20 |
| ATP | .95 |
1.08 |
1.29 |
1.79 |
1.41 |
1.22 |
1.08 |
| KLA/ATP | 1.36 |
1.35 |
2.04 |
2.81 |
2.07 |
1.44 |
1.19 |
|
Ifna2 | |
K01411 |
gb|Mouse alpha-interferon (MuIFN-alpha), 3 cds & untranslated mRNA [K01411] |
KLA | 1.02 |
1.03 |
1.10 |
.96 |
.93 |
.99 |
1.01 |
| ATP | 1.02 |
.98 |
1.00 |
.98 |
1.02 |
.97 |
.95 |
| KLA/ATP | 1.02 |
1.04 |
1.18 |
1.08 |
1.13 |
1.04 |
1.01 |
|
Ifna2 | |
NM_010503 |
interferon alpha 2 (Ifna2), mRNA [NM_010503] |
KLA | 1.08 |
1.06 |
1.07 |
1.06 |
.98 |
1.02 |
1.05 |
| ATP | .94 |
1.06 |
1.11 |
1.30 |
1.24 |
1.25 |
1.21 |
| KLA/ATP | 1.03 |
1.20 |
1.19 |
1.35 |
1.52 |
1.60 |
1.18 |
|
Ifna4 | |
NM_010504 |
interferon alpha 4 (Ifna4), mRNA [NM_010504] |
KLA | .99 |
1.04 |
1.05 |
.97 |
1.00 |
.96 |
.99 |
| ATP | 1.01 |
.96 |
.98 |
1.01 |
1.00 |
1.00 |
.97 |
| KLA/ATP | 1.10 |
1.09 |
1.05 |
1.04 |
1.01 |
.97 |
1.01 |
|
Ifna5 | |
NM_010505 |
interferon alpha 5 (Ifna5), mRNA [NM_010505] |
KLA | 1.15 |
1.23 |
1.51 |
1.26 |
1.03 |
1.06 |
1.05 |
| ATP | .99 |
.94 |
1.11 |
1.00 |
1.09 |
1.07 |
1.03 |
| KLA/ATP | 1.12 |
1.29 |
1.46 |
1.47 |
1.24 |
1.32 |
1.03 |
|
Ifna9 | |
NM_010507 |
interferon alpha 9 (Ifna9), mRNA [NM_010507] |
KLA | 1.05 |
1.09 |
1.20 |
1.06 |
1.08 |
1.06 |
1.02 |
| ATP | .99 |
1.08 |
1.18 |
1.21 |
1.09 |
.99 |
.97 |
| KLA/ATP | 1.09 |
1.23 |
1.19 |
1.24 |
1.18 |
1.16 |
1.04 |
|
Ifnab | |
BC116864 |
interferon alpha B, mRNA (cDNA clone MGC:151241 IMAGE:40126183), complete cds [BC116864] |
KLA | 1.20 |
1.33 |
1.29 |
1.30 |
1.20 |
1.20 |
1.08 |
| ATP | .99 |
.99 |
1.00 |
1.25 |
1.13 |
1.19 |
1.04 |
| KLA/ATP | 1.30 |
1.39 |
1.44 |
1.48 |
1.49 |
1.54 |
1.22 |
|
Ifnar1 | |
NM_010508 |
interferon (alpha and beta) receptor 1 (Ifnar1), mRNA [NM_010508] |
KLA | 1.35 |
1.29 |
1.19 |
1.39 |
1.60 |
1.47 |
1.49 |
| ATP | 1.18 |
1.25 |
.94 |
1.06 |
1.07 |
1.48 |
1.52 |
| KLA/ATP | 1.56 |
1.57 |
.98 |
1.43 |
1.08 |
1.79 |
3.54 |
|
Ifnar2 | |
NM_010509 |
interferon (alpha and beta) receptor 2 (Ifnar2), transcript variant 1, mRNA [NM_010509] |
KLA | 1.45 |
1.43 |
1.67 |
1.87 |
2.31 |
1.84 |
1.36 |
| ATP | .99 |
.92 |
.87 |
1.03 |
1.38 |
1.79 |
1.43 |
| KLA/ATP | 1.48 |
1.48 |
1.24 |
1.54 |
1.77 |
2.10 |
2.81 |
|
Ifnb1 | |
NM_010510 |
interferon beta 1, fibroblast (Ifnb1), mRNA [NM_010510] |
KLA | 49.82 |
46.57 |
34.05 |
16.05 |
5.94 |
7.31 |
8.49 |
| ATP | .99 |
1.02 |
1.89 |
4.78 |
6.31 |
4.44 |
1.79 |
| KLA/ATP | 49.22 |
61.83 |
134.08 |
144.05 |
110.96 |
31.78 |
11.24 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbke | |
NM_019777 |
inhibitor of kappaB kinase epsilon (Ikbke), mRNA [NM_019777] |
KLA | 6.03 |
5.91 |
6.38 |
6.89 |
7.05 |
6.70 |
4.74 |
| ATP | 1.02 |
1.11 |
.82 |
1.16 |
1.18 |
2.08 |
1.90 |
| KLA/ATP | 6.04 |
6.71 |
5.69 |
5.30 |
2.49 |
2.33 |
5.43 |
|
Ikbkg | |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg | |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg | |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Irf1 | |
NM_008390 |
interferon regulatory factor 1 (Irf1), mRNA [NM_008390] |
KLA | 10.08 |
9.47 |
8.27 |
7.31 |
6.74 |
6.39 |
3.17 |
| ATP | .95 |
.81 |
.80 |
3.61 |
2.99 |
4.15 |
1.77 |
| KLA/ATP | 10.40 |
10.08 |
6.59 |
8.23 |
12.18 |
7.53 |
7.82 |
|
Irf3 | |
ENSMUST00000107835 |
ens|Interferon regulatory factor 3 (IRF-3). [Source:Uniprot/SWISSPROT;Acc:P70671] [ENSMUST00000107835] |
KLA | .55 |
.56 |
.60 |
.72 |
.88 |
.88 |
.98 |
| ATP | .77 |
.58 |
.50 |
.46 |
.80 |
.97 |
1.03 |
| KLA/ATP | .51 |
.46 |
.49 |
.53 |
.92 |
.85 |
.79 |
|
Irf3 | |
NM_016849 |
interferon regulatory factor 3 (Irf3), mRNA [NM_016849] |
KLA | .79 |
.75 |
.71 |
.83 |
.88 |
1.07 |
.99 |
| ATP | .92 |
.84 |
.88 |
.61 |
.54 |
1.27 |
1.22 |
| KLA/ATP | .78 |
.78 |
.75 |
.58 |
.70 |
1.13 |
1.38 |
|
Irf7 | |
NM_016850 |
interferon regulatory factor 7 (Irf7), mRNA [NM_016850] |
KLA | 4.90 |
4.72 |
5.85 |
5.82 |
7.67 |
10.64 |
15.44 |
| ATP | 1.14 |
1.10 |
.86 |
1.18 |
.96 |
2.46 |
12.17 |
| KLA/ATP | 5.41 |
5.22 |
4.15 |
6.29 |
5.31 |
9.74 |
29.08 |
|
Irf9 | |
NM_008394 |
interferon regulatory factor 9 (Irf9), mRNA [NM_008394] |
KLA | 1.96 |
1.99 |
2.13 |
1.83 |
1.81 |
1.85 |
1.71 |
| ATP | 1.08 |
1.06 |
.96 |
1.19 |
1.21 |
2.33 |
2.42 |
| KLA/ATP | 2.31 |
2.30 |
1.92 |
2.85 |
2.29 |
3.20 |
4.37 |
|
Jak1 | |
AK029232 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831433J01 product:Janus kinase 1, full insert sequence. [AK029232] |
KLA | 1.25 |
1.13 |
1.19 |
1.31 |
1.24 |
1.17 |
1.14 |
| ATP | 1.01 |
1.11 |
.96 |
1.38 |
1.06 |
1.26 |
1.05 |
| KLA/ATP | 1.19 |
1.29 |
1.27 |
1.59 |
1.18 |
1.38 |
1.24 |
|
Jak1 | |
NM_146145 |
Janus kinase 1 (Jak1), mRNA [NM_146145] |
KLA | 1.71 |
1.75 |
1.79 |
1.81 |
1.72 |
1.37 |
1.21 |
| ATP | 1.03 |
1.01 |
.75 |
1.04 |
1.32 |
1.90 |
1.14 |
| KLA/ATP | 1.84 |
1.73 |
1.49 |
2.07 |
2.01 |
1.83 |
1.68 |
|
Kras | |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
Ldlr | |
NM_010700 |
low density lipoprotein receptor (Ldlr), mRNA [NM_010700] |
KLA | 2.17 |
2.00 |
2.07 |
1.87 |
1.38 |
.78 |
1.00 |
| ATP | .98 |
.87 |
1.53 |
1.14 |
1.01 |
1.52 |
1.60 |
| KLA/ATP | 1.86 |
1.76 |
2.52 |
1.55 |
1.59 |
.84 |
.82 |
|
Ldlr | |
Z19521 |
gb|M.musculus Ldlr mRNA encoding low density lipoprotein receptor. [Z19521] |
KLA | 1.94 |
1.93 |
2.24 |
2.01 |
1.73 |
1.08 |
1.26 |
| ATP | 1.12 |
1.21 |
1.47 |
1.65 |
1.28 |
1.45 |
1.67 |
| KLA/ATP | 2.22 |
2.28 |
2.17 |
2.27 |
1.50 |
1.13 |
1.29 |
|
Mapk1 | |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 | |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk10 | |
AK076990 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] |
KLA | 1.03 |
1.05 |
.98 |
1.04 |
.94 |
.95 |
1.02 |
| ATP | 1.00 |
.99 |
1.06 |
.97 |
1.01 |
.96 |
.99 |
| KLA/ATP | 1.07 |
1.01 |
.95 |
1.05 |
.82 |
.95 |
.87 |
|
Mapk10 | |
NM_009158 |
mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] |
KLA | .95 |
1.00 |
.97 |
1.01 |
.99 |
1.01 |
.95 |
| ATP | 1.01 |
1.02 |
.98 |
1.01 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.05 |
.99 |
1.01 |
.98 |
.92 |
.97 |
.98 |
|
Mapk11 | |
NM_011161 |
mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] |
KLA | 1.28 |
1.30 |
1.41 |
1.46 |
1.58 |
1.29 |
.98 |
| ATP | .96 |
.95 |
.89 |
.82 |
.79 |
1.09 |
.85 |
| KLA/ATP | 1.44 |
1.42 |
1.32 |
1.23 |
1.23 |
.74 |
.66 |
|
Mapk12 | |
NM_013871 |
mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] |
KLA | .94 |
.86 |
.87 |
.81 |
.77 |
.68 |
.49 |
| ATP | .97 |
.83 |
.92 |
.90 |
.86 |
.90 |
.51 |
| KLA/ATP | .91 |
.89 |
.88 |
.85 |
1.12 |
1.14 |
.53 |
|
Mapk13 | |
NM_011950 |
mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] |
KLA | 1.22 |
1.21 |
1.35 |
1.26 |
1.24 |
1.13 |
1.01 |
| ATP | 1.08 |
1.00 |
1.20 |
1.20 |
1.13 |
1.22 |
1.39 |
| KLA/ATP | 1.22 |
1.27 |
1.30 |
1.30 |
1.21 |
1.11 |
1.47 |
|
Mapk14 | |
NM_011951 |
mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] |
KLA | .70 |
.70 |
.62 |
.54 |
.67 |
.88 |
1.11 |
| ATP | 1.03 |
.98 |
.87 |
.69 |
.48 |
.78 |
.66 |
| KLA/ATP | .74 |
.68 |
.52 |
.46 |
.38 |
.45 |
.62 |
|
Mapk3 | |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mapk8 | |
AK162915 |
adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] |
KLA | .94 |
.86 |
.80 |
.83 |
.77 |
.85 |
.83 |
| ATP | 1.08 |
1.12 |
.94 |
.80 |
.83 |
.71 |
.75 |
| KLA/ATP | .83 |
.81 |
.80 |
.74 |
.74 |
.75 |
.67 |
|
Mapk8 | |
AK163829 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] |
KLA | .65 |
.61 |
.66 |
.70 |
.90 |
1.02 |
1.03 |
| ATP | .99 |
.94 |
1.68 |
1.44 |
1.75 |
1.84 |
1.10 |
| KLA/ATP | .63 |
.67 |
1.11 |
1.00 |
2.01 |
1.68 |
1.15 |
|
Mapk8 | |
NM_016700 |
mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] |
KLA | .96 |
1.00 |
.94 |
.96 |
.94 |
.99 |
1.04 |
| ATP | 1.01 |
1.05 |
1.01 |
.99 |
1.03 |
.98 |
1.02 |
| KLA/ATP | .96 |
.97 |
.96 |
.97 |
.93 |
.94 |
.96 |
|
Mapk9 | |
NM_016961 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] |
KLA | 1.28 |
1.37 |
1.59 |
1.60 |
1.61 |
1.43 |
1.38 |
| ATP | 1.03 |
.99 |
.74 |
.71 |
.79 |
1.20 |
1.01 |
| KLA/ATP | 1.53 |
1.30 |
1.07 |
.99 |
.83 |
1.10 |
1.40 |
|
Mapk9 | |
NM_207692 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] |
KLA | 1.39 |
1.53 |
1.69 |
1.69 |
1.55 |
1.44 |
1.51 |
| ATP | .95 |
.92 |
.75 |
.85 |
.70 |
1.46 |
1.17 |
| KLA/ATP | 1.37 |
1.35 |
.99 |
1.18 |
.91 |
1.22 |
1.62 |
|
Mm.10799 6 | |
94407580 |
Unknown |
KLA | .97 |
.95 |
.93 |
1.00 |
.95 |
1.00 |
1.00 |
| ATP | .95 |
1.03 |
.96 |
.92 |
1.03 |
.93 |
1.05 |
| KLA/ATP | .99 |
.91 |
.97 |
.92 |
.90 |
.90 |
.92 |
|
Mm.14301
| |
21630282 |
Unknown |
KLA | 3.97 |
3.92 |
3.89 |
4.78 |
4.16 |
4.22 |
3.83 |
| ATP | .97 |
.93 |
1.27 |
1.16 |
1.01 |
2.62 |
4.12 |
| KLA/ATP | 3.93 |
4.01 |
4.75 |
4.44 |
4.41 |
3.51 |
5.56 |
|
Mm.15909 3 | |
149272242 |
Unknown |
KLA | 1.01 |
.97 |
1.01 |
1.01 |
1.05 |
1.02 |
.99 |
| ATP | 1.04 |
1.01 |
.95 |
1.02 |
.99 |
.94 |
.96 |
| KLA/ATP | .96 |
1.01 |
1.04 |
.94 |
.94 |
1.05 |
.98 |
|
Mm.21312 8 | |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.22094 6 | |
27545180 |
Unknown |
KLA | 1.00 |
.93 |
.97 |
1.05 |
1.06 |
1.29 |
1.13 |
| ATP | .90 |
.94 |
1.25 |
1.18 |
.85 |
.62 |
1.20 |
| KLA/ATP | .86 |
.99 |
1.14 |
.99 |
.83 |
.70 |
1.26 |
|
Mm.25381 9 | |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.27970
| |
13994135 |
Unknown |
KLA | 1.06 |
1.11 |
1.16 |
1.07 |
1.11 |
1.08 |
.95 |
| ATP | 1.02 |
1.09 |
1.05 |
1.05 |
.94 |
1.16 |
1.32 |
| KLA/ATP | 1.10 |
1.19 |
1.11 |
1.04 |
1.08 |
1.02 |
1.33 |
|
Mm.37195 6 | |
94405889 |
Unknown |
KLA | 57.25 |
49.51 |
48.65 |
57.96 |
50.90 |
57.18 |
41.44 |
| ATP | 1.02 |
.90 |
1.21 |
1.10 |
2.19 |
27.45 |
33.37 |
| KLA/ATP | 48.99 |
49.58 |
73.18 |
63.02 |
73.34 |
72.06 |
76.66 |
|
Mm.37708 7 | |
158631169 |
Unknown |
KLA | .98 |
.98 |
1.06 |
1.06 |
.91 |
.97 |
1.04 |
| ATP | 1.00 |
1.07 |
1.01 |
1.06 |
1.09 |
.99 |
1.02 |
| KLA/ATP | 1.08 |
1.06 |
1.16 |
1.11 |
1.16 |
1.12 |
1.04 |
|
Mm.37899 0 | |
144227203 |
Unknown |
KLA | 5.51 |
4.67 |
4.55 |
6.22 |
4.34 |
4.26 |
2.87 |
| ATP | 1.00 |
.76 |
.68 |
.41 |
.53 |
3.65 |
1.93 |
| KLA/ATP | 4.53 |
4.63 |
5.45 |
2.73 |
3.51 |
4.58 |
3.75 |
|
Mm.4387 | |
133892666 |
Unknown |
KLA | .85 |
.87 |
.85 |
.89 |
.77 |
.91 |
1.18 |
| ATP | 1.01 |
1.01 |
.87 |
1.07 |
.75 |
.86 |
.93 |
| KLA/ATP | .88 |
.86 |
.77 |
.81 |
.72 |
.91 |
.84 |
|
Mm.46002 4 | |
38348245 |
Unknown |
KLA | 1.22 |
1.25 |
1.25 |
1.19 |
1.22 |
1.47 |
1.14 |
| ATP | 1.03 |
.94 |
1.01 |
1.01 |
2.67 |
2.31 |
1.37 |
| KLA/ATP | 1.35 |
1.19 |
1.27 |
1.22 |
1.99 |
1.83 |
1.45 |
|
Mm.47351 0 | |
162287332 |
Unknown |
KLA | 4.46 |
4.82 |
5.29 |
4.00 |
2.26 |
1.25 |
1.10 |
| ATP | 1.24 |
1.72 |
1.02 |
2.08 |
1.66 |
2.53 |
.55 |
| KLA/ATP | 6.11 |
7.67 |
4.29 |
6.99 |
3.11 |
2.86 |
2.30 |
|
Mm.57127
| |
117168292 |
Unknown |
KLA | 1.20 |
1.25 |
1.28 |
1.18 |
1.14 |
1.13 |
1.12 |
| ATP | .98 |
.95 |
1.11 |
1.06 |
1.05 |
1.05 |
1.09 |
| KLA/ATP | 1.22 |
1.24 |
1.48 |
1.55 |
1.40 |
1.21 |
1.07 |
|
Nfkb1 | |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 | |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkbia | |
NM_010907 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] |
KLA | 18.65 |
18.46 |
13.63 |
17.88 |
14.25 |
9.17 |
7.92 |
| ATP | .91 |
1.09 |
7.11 |
32.39 |
17.44 |
10.49 |
1.72 |
| KLA/ATP | 15.57 |
17.66 |
15.73 |
23.91 |
13.83 |
10.73 |
9.48 |
|
Nr1h3 | |
NM_013839 |
nuclear receptor subfamily 1, group H, member 3 (Nr1h3), mRNA [NM_013839] |
KLA | 1.80 |
1.74 |
1.73 |
2.19 |
4.14 |
5.99 |
8.67 |
| ATP | 1.12 |
.93 |
.69 |
.83 |
1.14 |
1.09 |
2.92 |
| KLA/ATP | 1.86 |
1.77 |
1.13 |
1.15 |
1.44 |
1.38 |
6.71 |
|
Nras | |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
OTTMUSG0 0000016644 | |
NM_001110517 |
predicted gene, OTTMUSG00000016644 (OTTMUSG00000016644), transcript variant 1, mRNA [NM_001110517] |
KLA | 111.73 |
107.32 |
111.47 |
133.12 |
110.94 |
145.92 |
83.83 |
| ATP | 1.00 |
.93 |
1.20 |
1.40 |
1.93 |
24.54 |
43.21 |
| KLA/ATP | 99.78 |
116.52 |
147.75 |
125.04 |
144.55 |
182.77 |
171.34 |
|
Oas1a | |
NM_145211 |
2-5 oligoadenylate synthetase 1A (Oas1a), mRNA [NM_145211] |
KLA | 2.26 |
2.33 |
2.50 |
2.33 |
3.11 |
3.74 |
3.99 |
| ATP | .99 |
1.04 |
.93 |
1.03 |
.91 |
1.63 |
3.44 |
| KLA/ATP | 2.49 |
2.39 |
1.91 |
2.51 |
2.28 |
3.09 |
6.06 |
|
Oas1b | |
NM_001083925 |
2-5 oligoadenylate synthetase 1B (Oas1b), mRNA [NM_001083925] |
KLA | 3.54 |
3.55 |
4.22 |
4.22 |
4.93 |
5.27 |
4.14 |
| ATP | 1.13 |
1.08 |
1.05 |
1.19 |
1.06 |
2.13 |
2.67 |
| KLA/ATP | 3.53 |
3.76 |
3.24 |
5.16 |
4.36 |
4.05 |
7.31 |
|
Oas1g | |
NM_011852 |
2-5 oligoadenylate synthetase 1G (Oas1g), mRNA [NM_011852] |
KLA | 2.58 |
2.75 |
2.53 |
2.84 |
2.60 |
2.74 |
2.56 |
| ATP | .97 |
1.03 |
1.20 |
1.17 |
1.07 |
1.82 |
2.47 |
| KLA/ATP | 2.58 |
2.80 |
2.68 |
2.60 |
2.21 |
2.27 |
3.01 |
|
Oas2 | |
NM_145227 |
2-5 oligoadenylate synthetase 2 (Oas2), mRNA [NM_145227] |
KLA | 3.37 |
3.26 |
3.43 |
2.80 |
3.59 |
3.57 |
2.15 |
| ATP | 1.10 |
1.20 |
1.04 |
.86 |
.94 |
3.23 |
3.09 |
| KLA/ATP | 3.85 |
3.75 |
3.15 |
3.70 |
4.00 |
5.52 |
7.31 |
|
Oas3 | |
NM_145226 |
2-5 oligoadenylate synthetase 3 (Oas3), mRNA [NM_145226] |
KLA | 2.32 |
2.35 |
2.67 |
2.63 |
3.37 |
3.80 |
4.07 |
| ATP | 1.06 |
1.10 |
1.02 |
1.26 |
1.02 |
1.47 |
3.58 |
| KLA/ATP | 2.62 |
2.57 |
2.39 |
3.18 |
2.67 |
3.05 |
6.15 |
|
Ocln | |
NM_008756 |
occludin (Ocln), mRNA [NM_008756] |
KLA | 1.02 |
1.04 |
1.03 |
1.03 |
.99 |
1.05 |
1.00 |
| ATP | 1.03 |
.98 |
1.01 |
1.07 |
1.05 |
1.05 |
1.04 |
| KLA/ATP | 1.09 |
1.00 |
1.03 |
1.05 |
1.06 |
1.03 |
1.01 |
|
Pdk1 | |
AK165090 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330005M21 product:hypothetical protein, full insert sequence. [AK165090] |
KLA | .86 |
.77 |
.71 |
.67 |
.45 |
.29 |
.35 |
| ATP | 1.06 |
.88 |
1.21 |
.72 |
.60 |
.26 |
.15 |
| KLA/ATP | .81 |
.74 |
.97 |
.57 |
.51 |
.22 |
.09 |
|
Pdk1 | |
NM_172665 |
pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA [NM_172665] |
KLA | .92 |
.94 |
.91 |
.79 |
.63 |
.46 |
.51 |
| ATP | .95 |
1.03 |
1.06 |
1.02 |
.63 |
.31 |
.37 |
| KLA/ATP | .88 |
.91 |
.91 |
.89 |
.62 |
.31 |
.27 |
|
Pias1 | |
NM_019663 |
protein inhibitor of activated STAT 1 (Pias1), mRNA [NM_019663] |
KLA | 1.60 |
1.58 |
1.85 |
1.69 |
1.49 |
1.22 |
1.00 |
| ATP | 1.09 |
1.10 |
.93 |
.86 |
.96 |
.68 |
.88 |
| KLA/ATP | 1.64 |
1.41 |
1.29 |
1.32 |
1.37 |
1.01 |
1.26 |
|
Pik3ca | |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca | |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb | |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd | |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd | |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg | |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 | |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 | |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 | |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 | |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Ppara | |
NM_011144 |
peroxisome proliferator activated receptor alpha (Ppara), transcript variant 1, mRNA [NM_011144] |
KLA | 1.01 |
3.31 |
.99 |
1.02 |
1.00 |
1.00 |
.98 |
| ATP | 1.00 |
1.02 |
.99 |
1.00 |
1.00 |
1.00 |
1.01 |
| KLA/ATP | 1.01 |
1.01 |
1.02 |
.99 |
1.00 |
1.02 |
.99 |
|
Ppp2ca | |
NM_019411 |
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform (Ppp2ca), mRNA [NM_019411] |
KLA | 1.17 |
1.13 |
1.18 |
1.20 |
1.54 |
1.45 |
1.34 |
| ATP | 1.09 |
1.20 |
1.07 |
1.33 |
1.56 |
2.04 |
1.43 |
| KLA/ATP | 1.14 |
1.17 |
1.15 |
1.49 |
1.59 |
2.37 |
2.02 |
|
Ppp2cb | |
NM_017374 |
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb), mRNA [NM_017374] |
KLA | 1.32 |
1.33 |
1.37 |
1.24 |
1.27 |
1.09 |
1.18 |
| ATP | .94 |
.93 |
.82 |
.91 |
1.22 |
2.01 |
1.08 |
| KLA/ATP | 1.24 |
1.14 |
.80 |
.97 |
1.13 |
1.54 |
1.18 |
|
Ppp2r1a | |
NM_016891 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (Ppp2r1a), mRNA [NM_016891] |
KLA | 1.44 |
1.39 |
1.47 |
1.37 |
1.69 |
1.33 |
1.16 |
| ATP | 1.18 |
1.55 |
.85 |
1.67 |
1.38 |
.99 |
1.24 |
| KLA/ATP | 1.66 |
1.98 |
.97 |
2.33 |
1.41 |
1.65 |
1.38 |
|
Ppp2r1b | |
NM_001034085 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 1, mRNA [NM_001034085] |
KLA | 1.26 |
1.17 |
1.14 |
1.13 |
1.12 |
1.11 |
.99 |
| ATP | .90 |
.90 |
.96 |
.98 |
1.59 |
1.71 |
1.16 |
| KLA/ATP | 1.23 |
1.16 |
.99 |
1.00 |
1.54 |
1.34 |
1.24 |
|
Ppp2r1b | |
NM_028614 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 2, mRNA [NM_028614] |
KLA | 2.38 |
2.38 |
2.53 |
1.80 |
1.52 |
.95 |
1.16 |
| ATP | 1.17 |
1.29 |
1.04 |
1.09 |
1.16 |
1.19 |
1.00 |
| KLA/ATP | 2.59 |
2.78 |
1.82 |
2.31 |
1.34 |
1.03 |
.75 |
|
Ppp2r2a | |
NM_028032 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform (Ppp2r2a), mRNA [NM_028032] |
KLA | 2.18 |
2.42 |
2.58 |
2.17 |
2.08 |
1.83 |
1.57 |
| ATP | 1.06 |
1.12 |
.90 |
1.28 |
1.76 |
1.70 |
1.39 |
| KLA/ATP | 2.55 |
2.38 |
1.62 |
2.68 |
2.25 |
2.55 |
1.86 |
|
Ppp2r2b | |
AK086561 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930037C08 product:unclassifiable, full insert sequence [AK086561] |
KLA | .94 |
1.02 |
1.07 |
1.02 |
1.02 |
.97 |
.98 |
| ATP | 1.01 |
1.04 |
1.01 |
.99 |
.97 |
.95 |
1.00 |
| KLA/ATP | 1.04 |
1.06 |
1.01 |
.96 |
1.02 |
.90 |
.93 |
|
Ppp2r2b | |
NM_028392 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (Ppp2r2b), transcript variant 2, mRNA [NM_028392] |
KLA | 1.01 |
1.02 |
.96 |
1.00 |
1.04 |
1.01 |
1.00 |
| ATP | 1.00 |
.96 |
1.07 |
.93 |
.95 |
1.01 |
1.03 |
| KLA/ATP | .95 |
1.01 |
1.06 |
1.07 |
.98 |
1.02 |
1.03 |
|
Ppp2r2c | |
NM_172994 |
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform (Ppp2r2c), mRNA [NM_172994] |
KLA | .97 |
.98 |
.96 |
1.02 |
1.02 |
1.06 |
1.01 |
| ATP | .96 |
1.05 |
1.03 |
.98 |
1.01 |
1.04 |
1.06 |
| KLA/ATP | .98 |
.98 |
1.00 |
.96 |
1.00 |
.86 |
1.10 |
|
Ppp2r2d | |
NM_026391 |
protein phosphatase 2, regulatory subunit B, delta isoform (Ppp2r2d), mRNA [NM_026391] |
KLA | 1.07 |
1.03 |
1.14 |
1.18 |
1.16 |
1.27 |
1.13 |
| ATP | .96 |
.93 |
.95 |
.76 |
1.34 |
2.21 |
1.22 |
| KLA/ATP | 1.01 |
1.01 |
1.01 |
.87 |
1.91 |
2.19 |
2.18 |
|
Psme3 | |
NM_011192 |
proteaseome (prosome, macropain) 28 subunit, 3 (Psme3), mRNA [NM_011192] |
KLA | 1.10 |
1.16 |
1.13 |
1.05 |
1.05 |
1.04 |
1.18 |
| ATP | 1.02 |
1.14 |
1.07 |
1.36 |
1.16 |
1.35 |
1.12 |
| KLA/ATP | 1.14 |
1.31 |
1.14 |
1.33 |
1.09 |
1.13 |
1.16 |
|
Raf1 | |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 | |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Rela | |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Ripk1 | |
NM_009068 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (Ripk1), mRNA [NM_009068] |
KLA | 1.32 |
1.33 |
1.50 |
1.09 |
1.00 |
1.11 |
1.13 |
| ATP | .98 |
.94 |
.60 |
.59 |
1.35 |
1.56 |
1.45 |
| KLA/ATP | 1.48 |
1.30 |
1.01 |
1.05 |
1.36 |
1.53 |
1.37 |
|
Rnasel | |
NM_011882 |
ribonuclease L (2, 5-oligoisoadenylate synthetase-dependent) (Rnasel), mRNA [NM_011882] |
KLA | .25 |
.24 |
.26 |
.35 |
.50 |
.47 |
.31 |
| ATP | .98 |
.91 |
.60 |
.40 |
.36 |
1.12 |
.53 |
| KLA/ATP | .24 |
.25 |
.23 |
.22 |
.32 |
1.16 |
.52 |
|
Rxra | |
NM_011305 |
retinoid X receptor alpha (Rxra), mRNA [NM_011305] |
KLA | .53 |
.55 |
.50 |
.52 |
.54 |
.85 |
1.09 |
| ATP | .95 |
1.00 |
1.18 |
1.00 |
.82 |
1.20 |
1.65 |
| KLA/ATP | .57 |
.55 |
.58 |
.55 |
.67 |
1.07 |
1.57 |
|
Scarb1 | |
NM_016741 |
scavenger receptor class B, member 1 (Scarb1), mRNA [NM_016741] |
KLA | .62 |
.60 |
.60 |
.51 |
.45 |
.40 |
.48 |
| ATP | 1.04 |
1.14 |
.68 |
.89 |
.53 |
.46 |
.82 |
| KLA/ATP | .73 |
.67 |
.40 |
.55 |
.34 |
.30 |
.39 |
|
Socs3 | |
NM_007707 |
suppressor of cytokine signaling 3 (Socs3), mRNA [NM_007707] |
KLA | 7.56 |
6.68 |
6.29 |
7.36 |
6.47 |
7.03 |
5.33 |
| ATP | 1.51 |
1.75 |
4.63 |
6.27 |
6.92 |
7.74 |
4.64 |
| KLA/ATP | 6.82 |
6.77 |
9.19 |
8.32 |
9.51 |
8.98 |
8.33 |
|
Sos1 | |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 | |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Stat1 | |
NM_009283 |
signal transducer and activator of transcription 1 (Stat1), mRNA [NM_009283] |
KLA | 2.90 |
2.72 |
3.00 |
3.64 |
4.58 |
6.51 |
5.58 |
| ATP | 1.01 |
.92 |
.89 |
.72 |
.51 |
2.22 |
3.07 |
| KLA/ATP | 2.73 |
2.65 |
2.34 |
1.95 |
1.99 |
4.70 |
8.66 |
|
Stat2 | |
NM_019963 |
signal transducer and activator of transcription 2 (Stat2), mRNA [NM_019963] |
KLA | 5.64 |
4.80 |
4.99 |
6.48 |
6.28 |
9.50 |
5.36 |
| ATP | .90 |
.80 |
1.03 |
.66 |
.97 |
4.90 |
4.07 |
| KLA/ATP | 4.47 |
4.88 |
6.34 |
4.27 |
6.76 |
9.49 |
11.43 |
|
Stat3 | |
NM_213659 |
signal transducer and activator of transcription 3 (Stat3), transcript variant 1, mRNA [NM_213659] |
KLA | 4.36 |
4.42 |
4.67 |
6.02 |
4.95 |
3.45 |
1.46 |
| ATP | 1.01 |
.97 |
1.07 |
1.17 |
2.47 |
4.04 |
1.47 |
| KLA/ATP | 4.02 |
4.57 |
6.65 |
6.51 |
7.06 |
7.39 |
3.61 |
|
Tbk1 | |
NM_019786 |
TANK-binding kinase 1 (Tbk1), mRNA [NM_019786] |
KLA | 2.55 |
2.76 |
3.22 |
2.67 |
2.56 |
2.29 |
1.96 |
| ATP | 1.13 |
1.30 |
1.12 |
1.07 |
1.29 |
1.41 |
1.40 |
| KLA/ATP | 2.84 |
3.17 |
2.58 |
2.43 |
1.70 |
2.15 |
2.37 |
|
Ticam1 | |
NM_174989 |
toll-like receptor adaptor molecule 1 (Ticam1), mRNA [NM_174989] |
KLA | 1.45 |
1.63 |
2.02 |
2.36 |
3.12 |
2.34 |
2.21 |
| ATP | 1.16 |
1.19 |
.90 |
2.58 |
4.78 |
2.04 |
1.80 |
| KLA/ATP | 1.79 |
1.71 |
1.07 |
2.89 |
5.60 |
3.26 |
3.50 |
|
Tlr3 | |
NM_126166 |
toll-like receptor 3 (Tlr3), mRNA [NM_126166] |
KLA | 8.54 |
10.04 |
12.64 |
11.83 |
10.51 |
7.08 |
3.09 |
| ATP | 1.09 |
1.16 |
1.16 |
1.16 |
.77 |
1.77 |
2.23 |
| KLA/ATP | 10.00 |
11.77 |
10.12 |
12.97 |
10.43 |
8.74 |
7.11 |
|
Tnf | |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfrsf1a
| |
NM_011609 |
tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] |
KLA | 1.74 |
1.71 |
1.90 |
2.16 |
1.95 |
1.74 |
1.16 |
| ATP | .95 |
.83 |
.55 |
.41 |
.41 |
1.55 |
1.32 |
| KLA/ATP | 1.58 |
1.49 |
1.19 |
1.03 |
.98 |
2.02 |
2.10 |
|
Tradd | |
NM_001033161 |
TNFRSF1A-associated via death domain (Tradd), mRNA [NM_001033161] |
KLA | .77 |
.71 |
.82 |
.89 |
.89 |
1.11 |
1.06 |
| ATP | 1.00 |
.90 |
1.01 |
.73 |
.59 |
1.34 |
1.50 |
| KLA/ATP | .79 |
.73 |
.83 |
.63 |
.72 |
1.11 |
1.73 |
|
Traf2 | |
NM_009422 |
Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] |
KLA | 3.38 |
3.62 |
3.49 |
3.36 |
3.49 |
3.39 |
2.68 |
| ATP | .97 |
1.04 |
1.00 |
1.10 |
1.54 |
2.40 |
1.55 |
| KLA/ATP | 3.38 |
3.16 |
2.93 |
2.74 |
2.67 |
3.11 |
4.70 |
|
Traf3 | |
NM_011632 |
Tnf receptor-associated factor 3 (Traf3), transcript variant 1, mRNA [NM_011632] |
KLA | .52 |
.49 |
.51 |
.49 |
.80 |
.98 |
1.22 |
| ATP | .93 |
.92 |
.95 |
1.13 |
2.70 |
1.80 |
1.42 |
| KLA/ATP | .56 |
.50 |
.49 |
1.07 |
2.94 |
1.92 |
1.65 |
|
Traf6 | |
NM_009424 |
Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] |
KLA | 1.19 |
1.28 |
1.34 |
1.20 |
1.23 |
1.23 |
1.28 |
| ATP | 1.06 |
1.12 |
.92 |
1.15 |
2.46 |
1.84 |
1.40 |
| KLA/ATP | 1.32 |
1.37 |
.89 |
1.16 |
1.45 |
1.49 |
1.46 |
|
Trp53 | |
NM_011640 |
transformation related protein 53 (Trp53), mRNA [NM_011640] |
KLA | 1.25 |
1.37 |
1.11 |
.86 |
.72 |
.71 |
.95 |
| ATP | 1.15 |
1.32 |
.90 |
1.85 |
1.26 |
.68 |
.70 |
| KLA/ATP | 1.66 |
1.49 |
.80 |
1.76 |
.81 |
.65 |
.74 |
|
Tyk2 | |
NM_018793 |
tyrosine kinase 2 (Tyk2), mRNA [NM_018793] |
KLA | 2.91 |
2.95 |
3.42 |
3.26 |
3.85 |
2.35 |
1.42 |
| ATP | 1.09 |
1.01 |
.68 |
.64 |
.59 |
.86 |
1.10 |
| KLA/ATP | 2.95 |
3.04 |
2.23 |
1.82 |
1.24 |
1.27 |
2.09 |
|